Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, Moussa SE, Neff GW, Rinella ME, Anstee QM, Abdelmalek MF, Younossi Z, Baum SJ, Francque S, Charlton MR, Newsome PN, Lanthier N, Schiefke I, Investigators M-N
It is undergoing Phase III trials to evaluate its safety in treating DED caused by dry eye syndrome (NCT05310422 and NCT04819269)
However, the best choice depends on your goals, side effect history, medication sensitivity, and provider guidance
Is the price for ten injections
The table is scientific and comparative in nature and does not constitute a direct head-to-head comparison or a claim about the effect of the research-grade product
Option B: Retatrutide-Led Stack with Low-Dose MOTS-c Best for: Researchers who want the primary fat-loss effects of retatrutide with MOTS-c as a supporting compound for insulin sensitivity